The Familywise Error Rate of a Simultaneous Confidence Band for the Net Health Benefit Function

2013 ◽  
Author(s):  
Morris Meisner ◽  
Eugene Laska ◽  
Carole Siegel ◽  
Joseph Wanderling
2002 ◽  
Vol 11 (3) ◽  
pp. 275-280 ◽  
Author(s):  
Morris Meisner ◽  
Eugene M. Laska ◽  
Carole Siegel ◽  
Joseph Wanderling

Author(s):  
Damian Clarke ◽  
Joseph P. Romano ◽  
Michael Wolf

When considering multiple-hypothesis tests simultaneously, standard statistical techniques will lead to overrejection of null hypotheses unless the multiplicity of the testing framework is explicitly considered. In this article, we discuss the Romano–Wolf multiple-hypothesis correction and document its implementation in Stata. The Romano–Wolf correction (asymptotically) controls the familywise error rate, that is, the probability of rejecting at least one true null hypothesis among a family of hypotheses under test. This correction is considerably more powerful than earlier multiple-testing procedures, such as the Bonferroni and Holm corrections, given that it takes into account the dependence structure of the test statistics by resampling from the original data. We describe a command, rwolf, that implements this correction and provide several examples based on a wide range of models. We document and discuss the performance gains from using rwolf over other multiple-testing procedures that control the familywise error rate.


2015 ◽  
Vol 14 (1) ◽  
pp. 1-19 ◽  
Author(s):  
Rosa J. Meijer ◽  
Thijmen J.P. Krebs ◽  
Jelle J. Goeman

AbstractWe present a multiple testing method for hypotheses that are ordered in space or time. Given such hypotheses, the elementary hypotheses as well as regions of consecutive hypotheses are of interest. These region hypotheses not only have intrinsic meaning but testing them also has the advantage that (potentially small) signals across a region are combined in one test. Because the expected number and length of potentially interesting regions are usually not available beforehand, we propose a method that tests all possible region hypotheses as well as all individual hypotheses in a single multiple testing procedure that controls the familywise error rate. We start at testing the global null-hypothesis and when this hypothesis can be rejected we continue with further specifying the exact location/locations of the effect present. The method is implemented in the


2020 ◽  
Vol 8 (2) ◽  
Author(s):  
Bumrungsak Phuenaree ◽  
Suttinee Kaewtaworn

The purpose of this research was to compare the efficiency of single-step procedures and the step-down procedures in order to test for multiple comparison with a control group. Four tests; Dunnett test, Step-down Dunnett test, Bonferroni test and Bonferroni-Holm test, was considered. The performance of these tests was evaluated in terms of the family wise error rate, any-pair power and all-pairs power. A Monte Carlo simulation was performed with repeated 10,000 times. The results showed that the familywise error rate of all test statistics closed to the nominal level. The empirical power of step-down procedures were higher than the single-step procedures, and the step-down Dunnett test gave the highest power.


Biometrika ◽  
2015 ◽  
Vol 102 (4) ◽  
pp. 767-782 ◽  
Author(s):  
Jesse Y. Hsu ◽  
José R. Zubizarreta ◽  
Dylan S. Small ◽  
Paul R. Rosenbaum

2019 ◽  
Vol 29 (5) ◽  
pp. 1315-1324
Author(s):  
John Spivack ◽  
Bin Cheng ◽  
Bruce Levin

We present a technique for adding dose modifications into seamless Phase II and Phase II/III trials featuring dose selection at an interim analysis. The method is convenient to apply and can be used either in a fully prespecified, structured way or as a response to new considerations that emerge at interim. Strong control of the familywise error rate regarding false declarations of efficacy versus control is maintained. Two examples are given. One illustrates how the method could potentially “save” a trial performed in a Phase II context. The other is a seamless Phase II/III trial that uses an adaptive exploration strategy for an assumed nonmonotonic dose-response curve. It can result in greatly improved efficiency over a standard “promote the winner” rule.


2020 ◽  
Vol 39 (9) ◽  
pp. 1407-1413 ◽  
Author(s):  
Michael A. Proschan ◽  
Erica H. Brittain

Sign in / Sign up

Export Citation Format

Share Document